BIIB vs REGN Stock Comparison

Biogen and Regeneron Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
BIIB Biogen Inc.
$253.40 +8.8% 1M +53.8% 1Y
Market cap
$37.15B
P/E
106.9x
Revenue (TTM)
$10.30B
Div. yield
–
Biotechnology Healthcare
1 win

Head to Head

11 decided of 12

Regeneron Pharmaceuticals leads on 10 of the 12 questions below (Regeneron Pharmaceuticals 10, Biogen 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBIIBREGNLeader
Larger companyMarket capitalisation $37.15B $96.53B REGN
Cheaper on earningsLower P/E, profitable companies only 106.9x 20.0x REGN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.5x 14.8x REGN
Faster revenue growthRevenue growth, trailing twelve months +2.3% +18.6% REGN
More profitableNet margin, trailing twelve months 3.4% 28.5% REGN
Better return on capitalReturn on invested capital 1.3% 11.9% REGN
Less leveragedLower net debt / EBITDA 4.5x -1.4x REGN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +53.8% +37.5% BIIB
Better 5-year returnAnnualised price return, 5 years -1.3%/yr +8.7%/yr REGN
Less volatileAnnualised volatility, 1 year 34.4% 33.9% REGN
Higher overall scoreMean of the five percentile scores vs peers 65/100 73/100 REGN

Percentile Scorecard

BIIBREGN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBIIBREGN
Valuation 91 #60 of 660 89 #75 of 660
Growth 27 #452 of 619 50 #308 of 619
Profitability 88 #73 of 595 92 #48 of 595
Financial Health 32 #466 of 683 71 #199 of 683
Shareholder Returns 90 #48 of 459 63 #170 of 459
Overall 65 73
  • BIIB ranked among 695 companies in Pharmaceuticals and Biotechnology
  • REGN ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBIIBREGNSPY
1 month +8.8%+22.8% -2.0%
3 months +20.8%+18.9% -2.8%
6 months +31.3%+36.8% +2.0%
Year to date +44.0%+23.8% +10.6%
1 year +53.8%+37.5% +12.2%
3 years +12.5%+20.4% +68.1%
3 years, per year +4.0%+6.4% +18.9%
5 years -6.3%+51.4% +61.4%
5 years, per year -1.3%+8.7% +10.1%
10 years -20.6%+127.6% +248.5%
10 years, per year -2.3%+8.6% +13.3%

Risk

MeasureBIIBREGNSPY
Volatility, 1Y 34.4%33.9% 13.6%
Downside volatility, 1Y 33.1%30.8% 13.9%
Beta vs S&P 500, 1Y 0.380.35 1.00
Return / volatility, 1Y 1.571.11 0.90
Max drawdown, 5Y -64.4%-59.8% -25.4%
From 52-week high -0.6%-1.8% -3.2%
52-week high $254.87$973.36 $779.14
52-week low $164.42$600.66 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBIIBREGN
P/E now vs peer median 107.8xmedian 17.0x 20.2xmedian 17.0x
P/S now vs peer median 3.6xmedian 8.4x 5.8xmedian 8.4x
EV/EBITDA now vs peer median 32.7xmedian 14.6x 16.7xmedian 14.6x
P/FCF now vs peer median 18.1xmedian 19.0x 25.4xmedian 19.0x
P/B now vs peer median 2.0xmedian 2.0x 2.9xmedian 2.0x
PEG now vs peer median -2.80median 0.43 2.23median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBIIBREGN
Revenue $10.30B $16.90B
Gross profit $7.62B $14.49B
Operating income $445.10M $4.86B
Net income $347.50M $4.82B
Free cash flow $2.07B $3.83B
R&D $2.15B $6.60B
EPS (diluted) $2.35 $45.62
Cash & equivalents $1.30B $3.66B
Total debt $7.29B $1.99B
Shares (diluted) 147.80M 105.60M
Enterprise value $26.46B $61.88B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBIIBREGN
P/E 107.8x 20.2x
P/FCF 18.1x 25.4x
P/Operating cash flow 16.7x 20.1x
P/S 3.6x 5.8x
P/B 2.0x 2.9x
P/Tangible book 6.8x 3.0x
EV/EBITDA 32.7x 16.7x
EV/EBIT 97.6x 18.5x
EV/Revenue 4.2x 5.3x
EV/FCF 21.0x 23.5x
EV/Operating cash flow 19.3x 18.5x
PEG (3Y EPS CAGR) -2.80 2.23

Growth

14 metrics
MetricBIIBREGN
Revenue growth (1Y) 2.3% 18.6%
Revenue CAGR (3Y) 1.0% 8.9%
Gross profit growth (1Y) 0.6% 19.1%
Gross profit CAGR (3Y) 0.5% 8.8%
Operating income growth (1Y) -76.6% 31.9%
Operating income CAGR (3Y) -34.8% 4.8%
Net income growth (1Y) -78.4% 5.2%
Net income CAGR (3Y) -38.1% 6.5%
EPS growth (1Y) -78.5% 6.8%
EPS CAGR (3Y) -38.5% 9.0%
Operating cash flow growth (1Y) -8.4% -4.4%
Operating cash flow CAGR (3Y) 18.2% -2.5%
Free cash flow growth (1Y) -10.1% -9.4%
Free cash flow CAGR (3Y) 24.9% -6.0%

Profitability

14 metrics
MetricBIIBREGN
Gross margin 74.0% 85.8%
EBITDA margin 12.9% 31.8%
Operating margin 4.3% 28.8%
Pretax margin 4.3% 33.7%
Net margin 3.4% 28.5%
FCF margin 20.1% 22.6%
Operating cash flow margin 21.8% 28.7%
Return on equity 1.8% 14.0%
Return on assets 1.1% 10.6%
Return on invested capital 1.3% 11.9%
Return on capital employed 1.6% 13.2%
Asset turnover 0.3x 0.4x
Cash conversion (OCF / net income) 6.5x 1.0x
Stock comp / revenue 2.9% 6.0%

Financial Health

11 metrics
MetricBIIBREGN
Debt / assets 22.7% 4.5%
Debt / equity 0.4x 0.1x
Net debt / EBITDA 4.5x -1.4x
Debt / FCF 3.5x 0.5x
Liabilities / assets 41.0% 24.6%
Equity / assets 59.0% 75.4%
Interest coverage – 104.2x
Current ratio 1.9x 3.4x
Quick ratio 0.9x 2.7x
Cash ratio 0.3x 1.5x
Altman Z-score 3.13 7.73

Shareholder Returns

7 metrics
MetricBIIBREGN
Dividend yield – 0.4%
Net buyback yield 0.1% 2.1%
Shareholder yield 0.1% 2.5%
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBIIBREGN
Forward P/E 19.5xFY2026 14.8xFY2026
EPS, next fiscal year $12.97FY2026 $64.62FY2026
EPS growth, next FY -15.1%FY2026 +45.8%FY2026
EPS growth, the year after +33.4% +13.6%
Revenue, next fiscal year $10.09BFY2026 $18.08BFY2026
Revenue growth, next FY +2.1%FY2026 +26.1%FY2026
Revenue growth, the year after +11.5% +14.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBIIBREGN
Held by institutions 96.4% 66.2%
Institutions holding 1,038 1,329
Change in shares held, QoQ +6.0% +3.8%
Institutions buying 549 607
Institutions selling 294 534
Buyers to sellers 1.87 1.14

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BIIBREGN
BIIB 1.00 0.33
REGN 0.33 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BIIB and REGN?

Regeneron Pharmaceuticals (REGN) is the largest by market capitalisation: Biogen (BIIB) $37.15B, Regeneron Pharmaceuticals (REGN) $96.53B.

Which stock is cheaper, BIIB and REGN?

Regeneron Pharmaceuticals (REGN) trades on the lowest price-to-earnings ratio (Biogen (BIIB) 106.9x, Regeneron Pharmaceuticals (REGN) 20.0x). On next year's consensus earnings, Regeneron Pharmaceuticals (REGN) is cheapest (Biogen (BIIB) 19.5x, Regeneron Pharmaceuticals (REGN) 14.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Regeneron Pharmaceuticals (REGN) grew revenue fastest over the trailing twelve months: Biogen (BIIB) +2.3%, Regeneron Pharmaceuticals (REGN) +18.6%.

Which company is more profitable?

Regeneron Pharmaceuticals (REGN) has the highest net margin (Biogen (BIIB) 3.4%, Regeneron Pharmaceuticals (REGN) 28.5%). On return on invested capital, Regeneron Pharmaceuticals (REGN) leads (Biogen (BIIB) 1.3%, Regeneron Pharmaceuticals (REGN) 11.9%).

Which stock has performed better?

Over the past year Biogen (BIIB) returned the most: Biogen (BIIB) +53.8%, Regeneron Pharmaceuticals (REGN) +37.5%. Over five years, Regeneron Pharmaceuticals (REGN) compounded fastest (Biogen (BIIB) -1.3%/yr, Regeneron Pharmaceuticals (REGN) +8.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Regeneron Pharmaceuticals (REGN) has been the steadiest (Biogen (BIIB) 34.4%, Regeneron Pharmaceuticals (REGN) 33.9%). Volatility measures how widely the price swings, not the risk of the business.

Do BIIB and REGN move together?

Their daily returns over the past year have a correlation of 0.33, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, BIIB and REGN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Regeneron Pharmaceuticals (REGN) leads on 10. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.